Expert view: High viscosity, high volume biologics call for new delivery device designs
Posted: 23 October 2020 | Owen Mumford | No comments yet
The increasing use of subcutaneous administration stems from the significant advances in biological drug development, as well as the rising trend of self-administration.
Further driving this movement is the growing number of biologics patents reaching expiry, thereby allowing the development of more affordable biosimilars. As intravenous drugs continue to be reformulated for subcutaneous administration, there is a growing need for safe and effective drug delivery device designs that can cope with the larger dose volumes and higher viscosity formulations typical of these drugs.
